When compared to general population, did patients with nonerosive gastroesophageal reflux disease have a similar incidence of esophageal adenocarcinoma?
When compared to general population, did patients with nonerosive gastroesophageal reflux disease have a similar incidence of esophageal adenocarcinoma?
Dr Dellon gave an oral paper presentation on efficacy and safety data for dupilumab in the treatment of eosinophilic esophagitis at the 2022 ACG Annual Scientific Meeting on October 24.
Dr Dellon gave an oral paper presentation on efficacy and safety data for dupilumab in the treatment of eosinophilic esophagitis at the 2022 ACG Annual Scientific Meeting on October 24.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
